Benazepril
- Generic Name
- Benazepril
- Brand Names
- Amlobenz, Lotensin, Lotensin Hct, Lotrel
- Drug Type
- Small Molecule
- Chemical Formula
- C24H28N2O5
- CAS Number
- 86541-75-5
- Unique Ingredient Identifier
- UDM7Q7QWP8
- Background
Benazepril, brand name Lotensin, is a medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic renal failure. Upon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor.
- Indication
Benazepril is indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics.
- Associated Conditions
- Diabetic Nephropathy, Heart Failure, Hypertension, Non-diabetic Nephropathy
- Associated Therapies
- -
Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy
- Conditions
- Interventions
- First Posted Date
- 2013-08-06
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 480
- Registration Number
- NCT01917149
- Locations
- 🇨🇳
Xijing Hospital, Department of Cardiology, Xi'an, China
Comparison Between Losartan and Benazepril in Diabetic Hypertensive Patients Not Controlled by Amlodipine
- First Posted Date
- 2012-05-23
- Last Posted Date
- 2016-02-01
- Lead Sponsor
- Hospital Universitario Pedro Ernesto
- Target Recruit Count
- 30
- Registration Number
- NCT01603940
- Locations
- 🇧🇷
Hospital Universitario Pedro Ernesto, Rio de Janeiro, RJ, Brazil
Low Dose Versus Aggressive Inhibition of the Renin-Angiotensin-Aldosterone (RAS) to Treat Microalbuminuria
- First Posted Date
- 2009-05-22
- Last Posted Date
- 2012-03-30
- Lead Sponsor
- Charles Drew University of Medicine and Science
- Target Recruit Count
- 46
- Registration Number
- NCT00907374
- Locations
- 🇺🇸
Charles Drew University, Los Angeles, California, United States
Renal Protective Effects of Renin Angiotensin System (RAS) Inhibitor in Peritoneal Dialysis Patients
- Conditions
- Interventions
- First Posted Date
- 2008-07-24
- Last Posted Date
- 2015-05-20
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 200
- Registration Number
- NCT00721773
- Locations
- 🇨🇳
The 1st Affiliated Hospital, Sun Yet-sen University, GuangZhou, Guangdong, China
Safety of Dual Blockage of Rennin-angiotensin System in Patients With Advanced Renal Insufficiency
- Conditions
- Interventions
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2016-04-05
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 309
- Registration Number
- NCT00630708
- Locations
- 🇨🇳
Renal Division, Nanfang Hospital,Southern Medical University, Guangzhou, Guangdong, China
Preventing Microalbuminuria in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2019-09-06
- Target Recruit Count
- 612
- Registration Number
- NCT00503152
- Locations
- 🇮🇹
Hospital "Casa Sollievo della Sofferenza" - Division of Endocrinology, San Giovanni Rotondo, Foggia, Italy
🇮🇹Azienda USL 2, Olbia, Italy
🇮🇹Hospital "Azienda Ospedaliera di Treviglio e Caravaggio" - Diabetologic Ambulatory of Ponte San Pietro, Ponte San Pietro, Bergamo, Italy
Preventing ESRD in Overt Nephropathy of Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2007-07-02
- Last Posted Date
- 2016-06-01
- Target Recruit Count
- 102
- Registration Number
- NCT00494715
- Locations
- 🇮🇹
Clinical Research Center for Rare Diseases "Aldo e Cele Daccò", Ranica, Bergamo, Italy
🇮🇹Hospital " Casa Sollievo della Sofferenza" - Unit of Nephrology, San Giovanni Rotondo, Foggia, Italy
🇮🇹University - AUSL 1 - Institute of Medical Pathology, Sassari, Italy
Long-Term Renoprotection of Optimal Antiproteinuric Doses of Benazepril and Losartan in Chronic Renal Insufficiency
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2006-06-20
- Lead Sponsor
- Southern Medical University, China
- Registration Number
- NCT00338091
- Locations
- 🇨🇳
Renal Division, Nanfang Hospital,Southern Medical University, Guangzhou, Guangdong, China
Benazepril for Advanced Chronic Renal Insufficiency
- Conditions
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2006-05-05
- Lead Sponsor
- Southern Medical University, China
- Registration Number
- NCT00270426
Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2012-01-18
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 152
- Registration Number
- NCT00185120
- Locations
- 🇺🇸
National Research Institute, Los Angeles, California, United States
🇺🇸Apex Research Institute, Santa Ana, California, United States
🇺🇸Orange County Research Center, Tustin, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.